Fundraising Fox
Cantai Therapeutics
Philadelpia, US · Founded 2023 · Delaware corporation · 5 employees on LinkedIn · 4 known investors
Find your way into Cantai Therapeutics
Sign up to see every warm intro you have to Cantai Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cantai Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.
Founders & leadership
Cantai Therapeutics was founded in 2023 by Errik Anderson.
Board
Investors · 4
How we know: Agent Capital's portfolio page · a partner's Signal profile · funding news · pulse2.com · Not right? Tell us
How we know: funding news · pulse2.com · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$4.3M disclosed across 3 rounds · 2023–2026
▶$3MraisedJan 2026 · 3 investors · BiotechnologyRule 506(b)
- Ross LeimbergExecutive Officer, Director
- Errik B. AndersonExecutive Officer
- Getta VemuriExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$550KraisedJul 2025 · 3 investors · BiotechnologyRule 506(b)
- Joshua BrandtDirector
- Errik AndersonExecutive Officer, Director
- Ross LeimbergExecutive Officer, Director
- Geeta VemuriExecutive Officer, Director
- Offering amount
- $1.1M
- Amount sold
- $550K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$700KraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
- Geeta VemuriExecutive Officer, Director
- Errik AndersonExecutive Officer, Director
- Ross LeimbergExecutive Officer
- Joshua BrandtExecutive Officer
- Offering amount
- $3M
- Amount sold
- $700K
- First sale
- Nov 2023
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Cantai Therapeutics went on to found or lead other companies.
Related companies · 4
Companies working in the same space as Cantai Therapeutics.
In the news
Frequently asked questions
- What does Cantai Therapeutics do?
- Cantai develops rationally designed bispecific antibodies that combine clinically validated mechanisms to treat patients with autoimmune disease. The company operates in the therapeutics and biotech space.
- Who founded Cantai Therapeutics?
- Cantai Therapeutics was founded by Errik Anderson in 2023.
- Who are Cantai Therapeutics's investors?
- Cantai Therapeutics's investors include Agent Capital, 82VS.
- How much funding has Cantai Therapeutics raised?
- Cantai Therapeutics has disclosed $4.3M raised across 3 rounds.
- Where is Cantai Therapeutics headquartered?
- Cantai Therapeutics is headquartered in Philadelpia, US.